Chemokine receptor CCR1: A new target for progressive kidney disease

25Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Infiltrating leukocytes are thought to contribute to the progression of kidney disease. Locally produced chemokines guide circulating leukocytes into the kidney, which renders therapeutic blockade of respective chemokine receptors on the leukocyte surface as potential targets forthe inhibition of renal leukocyte recruitment. By using mutant mice and specific antagonists, we found that chemokine receptor CCR1 has non-redundant functions for leukocyte adhesion to activated vascular endothelium and for transendothelial diapedesis. Most importantly, CCR1 blockade with a specific small molecule antagonist can improve injury in several types of progressive kidney disease models, even if treatment is initiated in advanced disease states. Identification of new targets may add to the therapeutic options in chronic kidney disease. Copyright © 2005 S. Karger AG.

Cite

CITATION STYLE

APA

Ninichuk, V., & Anders, H. J. (2005, July). Chemokine receptor CCR1: A new target for progressive kidney disease. American Journal of Nephrology. https://doi.org/10.1159/000087185

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free